NovoEight Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The novoeight market research report is one of a series of new reports that provides novoeight market statistics, including novoeight industry global market size, regional shares, competitors with a novoeight market share, detailed novoeight market segments, market trends and opportunities, and any further data you may need to thrive in the novoeight industry. This novoeight market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The growth in the forecast period can be attributed to rising patient awareness, increasing use of prophylactic treatment, home treatment and self-administration growth, expansion of hemophilia treatment centers, and growing government investments. Major trends in the forecast period include patient-centered innovation, innovations in biotechnology, integration of telemedicine, advanced treatment centers, and integration with electronic health records (EHRs)

The increasing prevalence of hemophilia is expected to drive the growth of the NovoEight market. Hemophilia is a genetic disorder where the blood fails to clot properly, leading to excessive bleeding even from minor injuries. The growing prevalence of hemophilia is largely due to advancements in diagnostic methods, increased awareness, and better reporting systems, resulting in more individuals being diagnosed with the condition. NovoEight helps individuals with hemophilia by effectively managing and preventing bleeding episodes, improving clotting function, and reducing the risk of spontaneous bleeding, which in turn enhances mobility and quality of life. For example, according to the World Federation of Hemophilia, 427,685 individuals worldwide were diagnosed with bleeding disorders in 2022, including 257,146 cases of hemophilia. As a result, the rising prevalence of hemophilia is driving market growth for NovoEight.

The growing demand for personalized medicine is also contributing to the growth of the NovoEight market. Personalized medicine tailors treatments to individual patients based on their genetic, environmental, and lifestyle factors. This shift is being fueled by advances in genetic research, greater awareness of personalized treatments, and a desire for more targeted therapies that minimize side effects while improving patient outcomes. NovoEight, a recombinant factor VIII therapy, fits within this trend by offering customized treatment options for patients with hemophilia A. Healthcare providers can adjust dosing regimens based on individual patient needs, genetic makeup, and therapy responses, thereby improving outcomes and overall quality of life. For instance, the Personalized Medicine Coalition reported that in 2023, the FDA approved 16 new personalized therapies for rare diseases, up from six in 2022. This increasing demand for personalized medicine is fueling the growth of the NovoEight market.

The rising healthcare expenditure is also expected to propel the growth of the NovoEight market. Healthcare expenditure encompasses the total resources spent on healthcare services and goods in a specific region or globally. Factors contributing to the rise in healthcare spending include aging populations, advancements in medical technologies, increased prevalence of chronic diseases, higher patient expectations, and inflation in healthcare costs. NovoEight, a recombinant factor VIII therapy, contributes to reducing healthcare expenditure by lowering the frequency of bleeding episodes and reducing the need for emergency interventions. This leads to better long-term management of hemophilia A, decreases overall treatment costs, and improves patients' quality of life. According to a December 2023 report by the Centers for Medicare & Medicaid Services, U.S. healthcare spending increased by 4.1% in 2022, reaching $4.5 trillion. Therefore, increasing healthcare expenditure is supporting the growth of the NovoEight market.

The key company operating in the novoeight market is Novo Nordisk A/S.

North America was the largest region in the novoeight market in 2024. The regions covered in novoeight report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the novoeight market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

NovoEight refers to turoctocog alfa, a recombinant coagulation factor VIII used to treat and prevent bleeding in individuals with hemophilia A, a genetic disorder characterized by a deficiency of factor VIII, an essential blood-clotting protein.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main indications for novoeight include hemophilia A and surgical procedures. Hemophilia A is a genetic disorder in which blood does not clot properly due to a lack of clotting factor VIII. NovoEight is distributed through hospital pharmacies, retail pharmacies, online pharmacies, and direct sales, and is used by a variety of end users, including pediatric and geriatric patients, as well as in hospitals, clinics, and homecare settings.

The novoeight market consists of sales of novoeight (recombinant factor VIII), novoseven (recombinant factor VII), novoeight [RFVIII] - lyophilized powder, and novoeight [RFVIII] prefilled syringe. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.